Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health bet...
Maxim Group analyst Caroline Palomeque upgrades Dare Bioscience (NASDAQ:DARE) from Hold to Buy and announces $8 price target.
Dare Bioscience (NASDAQ:DARE) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.6...
A first-of-its-kind solution for women's arousal in a proprietary topical formulation demonstrated to work where women need...
